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Ubiquitin and UBL (ubiquitin-like) modifiers are small proteins
that covalently modify other proteins to alter their properties
or behaviours. Ubiquitin modification (ubiquitylation) targets
many substrates, often leading to their proteasomal degradation.
NEDD8 (neural-precursor-cell-expressed developmentally down-
regulated 8) is the UBL most closely related to ubiquitin, and its
best-studied role is the activation of CRLs (cullin-RING ubiquitin
ligases) by its conjugation to a conserved C-terminal lysine
residue on cullin proteins. The attachment of UBLs requires three
UBL-specific enzymes, termed E1, E2 and E3, which are usually
well insulated from parallel UBL pathways. In the present study,
we report a new mode of NEDD8 conjugation (NEDDylation)
whereby the UBL NEDD8 is linked to proteins by ubiquitin
enzymes in vivo. We found that this atypical NEDDylation is
independent of classical NEDD8 enzymes, conserved from yeast
to mammals, and triggered by an increase in the NEDD8 to
ubiquitin ratio. In cells, NEDD8 overexpression leads to this
type of NEDDylation by increasing the concentration of NEDD8,
whereas proteasome inhibition has the same effect by depleting
free ubiquitin. We show that bortezomib, a proteasome inhibitor
used in cancer therapy, triggers atypical NEDDylation in tissue
culture, which suggests that a similar process may occur in
patients receiving this treatment.
Key words: bortezomib, MG132, MLN4924, neural-pre-
cursor-cell-expressed developmentally down-regulated 8
(NEDD8)-activating enzyme (NAE), proteasome, ubiquitin-
activating enzyme.
INTRODUCTION
Ubiquitin is a 76 amino acid protein that regulates various cellular
processes. It is best studied for its role in proteasome-depen-
dent protein degradation, but has also been shown to have
proteasome-independent functions in many signalling events [1].
The activity of ubiquitin is connected to its covalent conjugation
to other cellular proteins, where its C-terminus forms isopeptide
bonds with ε-amino groups of lysine residues. A three-step
enzymatic cascade is required to link ubiquitin to substrates
[2]. ATP-dependent activation of ubiquitin by either one of two
ubiquitin-activating enzymes (E1s), UBE1 or UBA6, initiates the
process [3]. Afterwards, ubiquitin is transferred to the active-site
cysteine of one of approximately 39 E2 enzymes [4] and then
linked to thousands of cellular substrates by the actions of a large
array of E3 ubiquitin ligases [1]. Often, ubiquitin is not only
conjugated as a single moiety, but rather forms chains of multiple
ubiquitin molecules linked via isopeptide bonds between the C-
terminal glycine residue of ubiquitin and one of the seven internal
lysine residues of the preceding ubiquitin in the chain. The signal
transduced by ubiquitin chains will vary depending on which
chain type is assembled. The best-studied chains are the ones
formed on Lys48, which in most cases trigger ubiquitin-dependent
degradation of the substrate by the proteasome [5]. Lys11-linked
chains seem to have a similar effect, whereas Lys63-linked and
linear chains are involved in signal transduction processes [6]. In
addition to ubiquitin, there are at least 17 UBL (ubiquitin-like)
molecules in the cell [7], most of which are also conjugated to
other cellular proteins. NEDD8 (neural-precursor-cell-expressed
developmentally down-regulated 8) is the ubiquitin-like modifier
most closely related to ubiquitin, with a high level of sequence
homology (58% identity and 80% similarity), as well as a very
similar three-dimensional structure [8]. NEDD8 utilizes a distinct
set of enzymes for conjugation to proteins [9]. NAE (NEDD8-
activating enzyme) is formed by a heterodimer of the two proteins
APPBP1 and UBA3. After activation, NEDD8 is transferred to
one of the two NEDD8-conjugating enzymes Ube2M [9] or
Ube2F [10], after which it is linked to its substrates via E3
enzymes. The only NEDD8-specific E3 complex identified to
date is a ligase consisting of the two E3s Dcn1 and Rbx1 [11–13],
whereas all other suggested NEDD8 ligases seem to have dual
activity for NEDD8 and ubiquitin.
The NEDD8 substrate spectrum appears to be far more limited
than the one for ubiquitin. The best-studied and most abundant
NEDD8 substrates are the cullin proteins. Cullins are scaffolds
for the largest class of ubiquitin E3 ligases, termed CRLs (cullin-
RING ubiquitin ligases). Cullin NEDDylation activates CRLs by
triggering structural changes and by counteracting the association
of the CRL inhibitor Cand1 [14,15]. In recent years, various non-
cullin NEDD8 substrates have also been identified, including p53,
Mdm2 (murine double minute 2), p73, L11, BCA3 (breast cancer-
associated gene 3), EGFR (epidermal growth factor receptor),
VHL (von Hippel–Lindau protein), HIF1α (hypoxia-inducible
factor 1α), XIAP (X-linked inhibitor of apoptosis) and caspase
7 [16–23]. Proteomic approaches to identify NEDD8 substrates
have in addition been undertaken [24–26]. The effect of NEDD8
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conjugation for a particular protein differs; reported consequences
include effects on stability, transcriptional activity and subcellular
localization [16,22,27].
In the present study we report an unexpected crosstalk between
the NEDD8 and ubiquitin pathways. We show that increases
in the free NEDD8 to ubiquitin ratio trigger activation of NEDD8
by the ubiquitin E1 enzyme in cells (atypical NEDDylation),
which probably leads to a global attenuation of ubiquitin-
dependent protein degradation. The physiological significance
of this effect remains unclear; however, the approved anti-
cancer drug bortezomib causes atypical NEDDylation in cultured
cells due to depletion of free ubiquitin, which possibly affects
therapeutic outcome. Our results emphasize that understanding
substrate and UBL specificity within these pathways is important
for evaluating potential drugs, but also needs to be taken into
consideration when defining the NEDDylated and ubiquitylated
proteomes.
EXPERIMENTAL
MLN4924 synthesis
((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-
pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl
sulfamate, the compound that is MLN4924 (referred to
throughout as such), was synthesized as described previously
[28].
Cell culture and transfection
U20S, HEK (human embryonic kidney)-293 and HeLa cells
were grown in DMEM (Dulbecco’s modified Eagle’s medium;
GIBCO) supplemented with 10% FBS (fetal bovine serum;
GIBCO) and 100 units/ml penicillin/100 μg/ml streptomycin
(Intvitrogen). CHO (Chinese-hamster ovary) TS41 cells were
grown at 32 ◦C in F-12K (GIBCO) supplemented with 10%
FBS (Gibco) and penicillin/streptomycin (Invitrogen). MG132
and bortezomib were from Sigma–Aldrich and LC Laboratories
respectively. All plasmid transfections were performed using
LipofectamineTM LTX PLUS (Invitrogen), following the
manufacturer’s instructions. For pCMV5-NEDD8/NEDD8GG
overexpressions, unless stated otherwise, 1 μg of plasmid was
transfected per six-well plate, containing approximately 1.5×105
cells. For HA (haemagglutinin)–UBE1 immunoprecipitations,
approximately 1×106 cells per 100 mm dish were co-transfected
with 5 μg of pCMV HA-UBE1WT/HA-UBE1C632S (where
WT is wild-type) and 5 μg of untagged pCMV5-NEDD8.
All UBE1 and UBE1L2 siRNA (small interfering RNA)
transfections were performed using Dharmacon ON-TARGET
plus SMARTpool siRNA oligos at a final concentration of 20 nM
and LipofectamineTM RNAiMAX (Invitrogen), according to the
manufacturer’s instructions. All UBE1 and UBA6 (UBE1L2)
knockdowns were performed 48 h prior to plasmid transfections,
and for a total of 72 h.
In vitro NEDD8/ubiquitin activation/transfer assays
His6–UBE1 (6 pmol; Ubiquigent) was added to 20 μl of reaction
buffer (50 mM Hepes, pH 7.5, 100 mM MgCl2 and 2 mM
MgATP) containing 2.5 μM ubiquitin E2 (Ubiquigent). For E1
activation assays, E2 enzymes were left out. The reaction was
started by addition of either 2 nmol of purified ubiquitin or 2
nmol of purified NEDD8, incubated at 30 ◦C and stopped after
30 min by addition of reducing or non-reducing 3× Laemmli
buffer.
Immunoprecipitations
HA immunoprecipitations were performed under denaturing
conditions. Cells were lysed in 1% SDS, 5 mM EDTA, 10 mM
iodoacetamide, 15 units/ml DNase I (Qiagen) and 1× CompleteTM
protease inhibitor cocktail (Roche). Lysis was performed on
ice, followed by immediate heating of the samples to 95 ◦C,
after which lysates were diluted 10-fold with 20 mM Tris/HCl,
pH 8, 137 mM NaCl, 10% glycerol, 1% Nonidet P-40, 2 mM
EDTA, 10 mM iodoacetamide and 1× CompleteTM protease
inhibitor cocktail. DNA was fragmented by passing lysates
through a syringe. Lysates were precleared for 1 h rotating at 4 ◦C
with control agarose beads (Pierce, 26150), after which lysates
were incubated with anti-HA beads (Sigma–Aldrich, A2095).
Immunprecipitation was performed at 4 ◦C for 1 h with rotation.
Beads were washed, and bound proteins were eluted by addition
of low pH buffer (50 mM glycine, pH 2.8). Eluted samples were
split into two, and either reducing or non-reducing 3× Laemmli
buffer supplemented with 8 M urea was added 1:1.
Western blotting and antibodies
Anti-NEDD8 antibodies used were: rabbit ALX-210-194 (Alexis
Biochemical), rabbit MIL-10 (Millennium Pharmaceuticals),
rabbit #2745 (Cell Signaling Technology), rabbit #2754
(Cell Signaling Technology), rabbit BML-PW9340 (ENZO
Lifesciences) and rabbit A-812 (BostonBiochem). Anti-
ubiquitin antibodies used were: mouse P4D1 (Santa Cruz
Biotechnology), mouse MAB1510 (Millipore) and rabbit Z0458
(DakoCytomation). All of the above antibodies were used at a
dilution of 1:3000, with the exception of MIL-10, which was
used at 1:10000. Rabbit anti-UBE1 Ab34711 (Abcam), anti-
UBE1L2 antibody (Abcam) and rabbit anti-actin Ab1801-100
were all used at 1:3000. Mouse anti-HA HA.11 16B12 (Covance)
and anti-HA HRP (horseradish peroxidase) clone HA-7 (Sigma–
Aldrich) were used at 1:2000. Anti-FLAG HRP (Sigma–Aldrich)
was used at 1:2000. The goat anti-mouse 170-5046 and goat
anti-rabbit 170-5047 secondary antibodies (Bio-Rad) were used
at 1:5000. Western blotting was performed using AmershamTM
HybondTM ECL (enhanced chemiluminescence) nitrocellulose
membranes (GE Healthcare) with 5% non-fat dried skimmed
milk powder/2% BSA blocking agent and standard laboratory
techniques.
PPi exchange and kinetic thioester experiments
[32P]PPi and [α-32P]ATP were obtained from PerkinElmer.
Bovine ubiquitin was purchased from Sigma (U6253). NEDD8
was generated in an untagged form in a pDEST vector
and was expressed in Escherichia coli. N-terminal His6-tagged
E1 enzymes (UBE1 and NAE) were expressed in Sf9 insect cells
and purified as described previously [30]. Mouse monoclonal
anti-FLAG M2 antibody was purchased from Sigma (F1804).
Alexa Fluor® 680-labelled secondary antibodies were purchased
from Invitrogen (A21109 for anti-rabbit antibody and A21057
for anti-mouse antibody). The ATP–PPi exchange assays were
performed using an improved protocol developed by Bruzzese
et al. [30]. The final reaction mixture of 50 μl contained 2.5–
20 nM UBE1 or NAE, 0.6 μM ubiquitin or 0.2 μM NEDD8 for
UBE1 reactions, 0.16 μM NEDD8 for NAE reactions, 100 μM
ATP, 0.5 mM PPi, ∼50 c.p.m./pmol [32P]PPi, 10 mM MgCl2 and
1 mM TCEP [tris-(2-carboxyethyl)phosphine], in 1× E1 buffer
(50 mM Hepes, pH 7.5, 25 mM NaCl, 0.05% BSA and 0.01%
Tween 20). Reactions were initiated by adding E1 enzymes and the
reaction mixtures were incubated at 37 ◦C. At various time points,
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the reaction was quenched with 5% (w/v) TCA (trichloroacetic
acid) containing 10 mM PPi. The quenched reaction mixtures
were transferred to a Schleicher & Schuell Minifold-I Dot-Blot
System (Whatman; 10447900) with activated charcoal filter paper
(Whatman; 10320163) pre-rinsed in 2% TCA and 10 mM PPi,
which was then washed for 3×5 min in the same solution. The
charcoal filter paper blots were air dried, exposed to an imaging
plate for 1 h and visualized using a phosphorimager (Fujifilm
FLA-7000; GE Healthcare). Samples from each time point were
analysed in duplicate. The spot intensities were converted into the
quantity of ATP using a standard curve generated with [α-32P]ATP.
Rate of UBE1-S–NEDD8 and NAE (UBA3) thioester formation
For UBE1, the reaction mixture contained 1.5 μM UBE1, 1 μM
NEDD8, 100 μM ATP in 10 mM MgCl2 and 50 mM Hepes,
pH 7.5, and was incubated at 37 ◦C. For NAE, the reaction
mixture contained 1 μM NAE, 5 μM NEDD8, 25 μM ATP in
5 mM MgCl2 and 20 mM Hepes, pH 7.5. At designated time
points, the reaction mixture was quenched with LDS (lithium
dodecyl sulfate) sample loading buffer (Invitrogen; the 4×
solution contained 40% glycerol, 4%, LDS 4% Ficoll-400,
0.8 M triethanolamine-Cl pH 7.6, 0.025% Phenol Red, 0.025%
Coomassie Blue G250 and 2 mM EDTA). The quenched samples
were analysed by SDS/PAGE under non-reducing conditions.
Samples from each time point were analysed in duplicate.
The SDS/PAGE gels were transferred to a 0.2 μm-pore-size
Immobilon-P PVDF membrane (Millipore; ISEQ20200) and
probed with rabbit anti-NEDD8 or mouse anti-FLAG antibodies.
Alexa Fluor® 680-labelled secondary antibody was then used
and the intensities of protein bands were quantified on a Li-Cor
Odyssey Imaging System (Li-Cor Biosciences).
Competition assay to estimate the affinity of NEDD8 for UBE1
In the competition experiment using the ATP–PPi exchange
assay, the reaction mixtures containing 0.5 nM UBE1, 0.6 μM
N-terminal FLAG-tagged ubiquitin, 1 mM ATP, 0.5 mM PPi
(∼100 c.p.m./pmol [32P]PPi) and various amounts of NEDD8
in 1× E1 buffer were incubated at 37 ◦C for 30 min, quenched
and analysed as described above. To monitor competition of
NEDD8 in UBE1-S–ubiquitin thioester assays, reaction mixtures
containing 50 nM UBE1, 0.8 μM ubiquitin, 1 mM ATP, 10 mM
MgCl2 and various amounts of NEDD8 (up to 184 μM) in 1×
E1 buffer were incubated at 37 ◦C for 15 min and quenched with
the LDS loading buffer. The UBE1 thioester levels were analysed
using non-reducing SDS/PAGE and Western blot analysis Li-Cor
imaging as described above.
Quantification of NEDD8 and ubiquitin
For NEDD8 quantifications, U2OS cells were transfected with
the indicated plasmids 24 h prior to harvest. For ubiquitin
and NEDD8, cells were treated with 30 μM MG132 or 3 μM
MLN4924 for 4 h as indicated. Cells were harvested by
trypsination and counted, followed by immediate lysis in reducing
or non-reducing Laemmli buffer, supplemented with 8 M urea. A
minimum of three independent repeats was performed for all
points. Quantification of NEDD8 and ubiquitin was performed
by Western blot analysis using standard curves based on known
amounts of purified protein. Data acquisition and densitometric
analysis was performed using the ChemiDocTM XRS system
and Image Lab software respectively (Bio-Rad). Estimations of
NEDD8 and ubiquitin levels were based on interpolation within
linear ranges.
Saccharomyces cerevisiae experiments and strains
For overexpression of Rub1, pRD54-HA-Rub1 or pRD54-HA-
Rub1GG was transformed into S. cerevisiae S288c using one-
step transformation, and expression was induced by addition
of 2% final concentration galactose. Extracts were prepared
using the TCA precipitation protocol, and resuspended in 3×
Laemmli buffer supplemented with 8 M urea. The yeast deletion
strains ubc12, rub1 and uba3 were obtained from the
Euroscarf haploid knockout collection. Double deletion mutants
were generated by PCR-based knockout methods. Strain uba1-
204 and the isogenic WT were from Professor Raymond
Deshaies (Division of Biology, California Institute of Technology,
Pasadena, CA, U.S.A.). The TRP1 N-end rule reporter strains
were obtained from Professor Daniel Finley (Department of Cell
Biology, Harvard Medical School, Boston, MA, U.S.A.). Growth
assays were performed by serial dilution and spotting on to
tryptophan-deficient glucose or galactose agar plates as indicated.
RESULTS
UBE1 activates NEDD8 in vitro
To better characterize the NEDDylated proteome, it is import-
nt to understand the pathways mediating the modification.
Owing to the high similarity between ubiquitin and NEDD8, we
explored whether ubiquitin enzymes can NEDDylate proteins by
quantifying the potential for UBE1 to activate NEDD8 in vitro
[8]. In endpoint activation assays, we detected thioester formation
between UBE1 and ubiquitin or NEDD8, but not with the more
distantly related UBL SUMO1 (small ubiquitin-like modifier 1)
(Figure 1A). Furthermore, UBE1 could transfer NEDD8 to 28
ubiquitin E2 enzymes (Figure 1B and Supplementary Table S1 at
http://www.BiochemJ.org/bj/441/bj4410927add.htm), but not the
SUMO E2 Ube2I (Ubc9) or the two NEDD8 E2s Ube2M (Ubc12)
and Ube2F. Thus UBE1 is able to activate NEDD8 and feed it into
the ubiquitin pathway.
We next determined the kinetics of the UBE1–NEDD8 charging
reaction, using PPi exchange assays [30]. The UBE1–NEDD8 re-
action was approximately 100-fold less efficient than the activity
of NEDD8 with NAE and 200-fold less efficient than the
activity of ubiquitin with UBE1 (Figure 1C). We further measured
the rate of UBE1–NEDD8 thioester formation using a stop-
flow instrument and Western blotting. The observed rate of
kobs = 8.1 +− 1.2×10− 3 s− 1 (Figure 1D) was 380-fold less efficient
than thioester formation of NAE (UBA3) with NEDD8 (Fig-
ure 1E). Thus, even though NEDD8 can be activated by UBE1, the
reaction is slow and ubiquitin is a significantly better substrate.
In vitro UBE1 activates NEDD8 and ubiquitin in parallel
In the cell, ubiquitin and NEDD8 would probably simultaneously
compete for UBE1. To determine if in this situation NEDD8 could
still be activated, we next performed an in vitro competition assay
using thioester formation as readout with fixed amounts of UBE1
(100 nM) and ubiquitin (0.8 μM) and increasing amounts of
NEDD8 (Figure 1F). Consistent with the less efficient activation
of NEDD8 by UBE1, only minor competition with ubiquitin
at high concentrations of NEDD8 (>100 μM) was detectable
(Figure 1F). However, UBE1–NEDD8 thioester formation was
apparent at a concentration of ∼6 μM NEDD8, albeit at a low
level. Thus activation of NEDD8 by UBE1 can occur in vitro even
in the presence of ubiquitin, but requires at least a 7-fold excess
of NEDD8. Both activities may thus also take place in parallel in
the cell, in situations where the levels of free NEDD8 exceed that
of free ubiquitin.
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Figure 1 Assessment of the capacity of UBE1 to activate NEDD8 in vitro
(A) Coomassie Blue-stained gel of UBE1 charging reaction with either ubiquitin, NEDD8 or SUMO1. A bandshift under non-reducing conditions [ − DTT (dithiothreitol)] indicates successful
charging. (B) UBE1 can transfer both NEDD8 and ubiquitin to a panel of ubiquitin E2s, but not to the NEDD8 E2s Ube2M and Ube2F or the SUMO E2 Ube2I. (C) Quantification of ATP–PPi exchange
reaction monitoring the specific activity of UBE1 towards ubiquitin and NEDD8 and NAE towards NEDD8. The activity of UBE1 with NEDD8 is roughly 100- and 200-fold slower than NAE with NEDD8
and UBE1 with ubiquitin respectively. (D and E) Quantification of the rate of NEDD8 thioester formation on UBE1 and NAE (UBA3). Thioester formation of NAE with NEDD8 is 380-fold faster than
thioester formation of NEDD8 with UBE1. (F) Thioester competition assay determining the capacity of NEDD8 to form a thioester intermediate with UBE1 (50 nM) when competing with ubiquitin
(0.8 μM). A 7-fold excess of NEDD8 is minimally required for parallel activation of both UBLs. A.U., absorbance units; Ub, ubiquitin.
Free NEDD8 and ubiquitin are present at approximately equimolar
amounts in cells
To estimate whether such a situation could occur, we next
measured the cellular concentration of free ubiquitin and
NEDD8 using MIL-10 NEDD8 and Z0458 ubiquitin antibodies
(for antibody specificity data, see Supplementary Figure S1
at http://www.BiochemJ.org/bj/441/bj4410927add.htm). The
measurements were performed under non-reducing conditions to
preserve thioesters on the E1, E2 and E3 enzymes. We used
standard curves based on known protein amounts (R2 > 0.98)
to estimate protein content in cell extracts by interpolation
(Figures 2A and 2B). Assuming an average cellular volume
of 1 pl, the concentration of free NEDD8 in U2OS cells was
∼29 μM and that of free ubiquitin was ∼25.6 μM (Figures 2C
and 2D). Free NEDD8 and ubiquitin are thus present at
roughly equimolar amounts; similar values were reproduced
using another cell line (MCF7; see Supplementary Figure S2
at http://www.BiochemJ.org/bj/441/bj4410927add.htm). Accord-
ing to the in vitro results, this concentration would not allow
activation of NEDD8 by UBE1; however, relatively small changes
in the concentration of either UBL could be sufficient to trigger
the process.
NEDD8 overexpression triggers UBE1-dependent NEDDylation
We next overexpressed an HA-tagged form of NEDD8 in U2OS
cells, to test whether increases in the relative concentration of
NEDD8 over ubiquitin causes UBE1-dependent NEDDylation.
Overexpression increased the cellular concentration of free
NEDD8 to 173 μM (Figure 2C), which translated into an increase
in the ratio of free NEDD8 to ubiquitin from 1:1 to 6.8:1
(Figure 3A). This corresponds roughly to the minimal amount
required for activation by UBE1 in vitro (Figure 1F). Moreover,
overexpression of HA–NEDD8GG, a non-conjugatable form
of NEDD8 from which the two C-terminal glycine residues
were deleted, increased the concentration of free NEDD8
to 415 μM. This result suggests that roughly 60% of the
overexpressed NEDD8 is converted into conjugates, possibly by
UBE1 (Figure 2C).
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Figure 2 Intracellular concentrations of endogenous free NEDD8 and ubiquitin
(A and B) Purified NEDD8 and ubiquitin was used to construct standard curves. Data points represent means +− S.D. Lower panels show representative images of standards. A.U., absorbance
units. (C) Endogenous intracellular concentrations of free NEDD8 (μg) in U2OS cells under the indicated conditions, as well as intracellular concentration of overexpressed mature NEDD8 and
NEDD8GG. A representative Western blot is shown in the bottom panel, with estimated amounts of free NEDD8 (ng) calculated by interpolation. (D) Endogenous levels of non-conjugated ubiquitin
were evaluated under MG132 (30 μM, 4 h) and control (DMSO) conditions. Data points in (C) and (D) represent means +− S.D.
Indeed, the NEDDylation pattern of cells overexpressing
NEDD8 was vastly different from non-overexpressing cells.
Endogenous NEDD8 formed very few conjugates, which by mo-
lecular mass corresponded to NEDDylated cullins and thioesters
with the NEDD8 E2 enzymes and E1 (Figure 3B). Treatment with
MLN4924 abolished this NEDDylation, demonstrating the
dependence on the classical NEDD8 pathway. NEDD8-
overexpressing cells, however, displayed numerous NEDD8
substrates covering almost the entire molecular mass range
of the gel (Figure 3C). Expression of the non-conjugatable
form of NEDD8 (HA–NEDD8GG) did not result in
this extensive NEDDylation pattern (Supplementary Figure
S3A at http://www.BiochemJ.org/bj/441/bj4410927add.htm),
demonstrating that this atypical NEDDylation represents
conjugation of NEDD8 to proteins. Furthermore, treatment with
MLN4924 had no affect on this type of NEDDylation (Fig-
ure 3C). Rather, siRNA to the ubiquitin E1 enzyme UBE1
(Figure 3C), but not UBA6 (see Supplementary Figure S4
at http://www.BiochemJ.org/bj/441/bj4410927add.htm), strongly
reduced its appearance. Importantly, cullin NEDDylation was
unaffected by down-regulation of the ubiquitin-activating enzyme
and this phenomenon was also observed in other cell lines
(Figure 3C and Supplementary Figure S4). Treatment with
the UBE1 inhibitor PYR-41 [31] also diminished atypical
NEDDylation (Supplementary Figure S3B), suggesting that it is
indeed mediated by the ubiquitin E1 enzyme.
MG132 treatment lowers free ubiquitin levels and triggers
UBE1-dependent NEDDylation
Next, we wanted to test if increasing the relative concentration of
free NEDD8 to ubiquitin by lowering the levels of free ubiquitin
also triggers atypical NEDDylation. To efficiently reduce the
free ubiquitin levels, we exposed cells to the proteasome
inhibitor MG132, which leads to the accumulation of ubiquitin
in high molecular mass conjugates [32]. MG132 treatment
reduced the free ubiquitin concentration to 8.1 μM, whereas
free NEDD8 was unaffected (Figures 2C and 2D). Consequently,
the NEDD8 to ubiquitin ratio increased to 3.6:1, approximately
half the minimal amount required to trigger UBE1-dependent
NEDDylation in vitro (Figure 1F). Nevertheless, this increase was
sufficient to trigger widespread UBE1-dependent NEDDylation
(Figure 3D). We concluded that both increases in NEDD8 levels
and decreases in free ubiquitin levels can trigger UBE1-dependent
NEDDylation, and that this system is probably more sensitive to
lower ubiquitin levels than to excess NEDD8.
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Figure 3 Perturbing the NEDD8 to ubiquitin ratio leads to UBE1-dependent NEDDylation
(A) Ratios of free NEDD8 to ubiquitin under the indicated conditions, and after expression of different forms of NEDD8. Error bars represent +− S.D. (B) Pattern of endogenous NEDD8 conjugates in
U2OS cells under non-reducing [ − BME (2-mercaptoethanol)] and reducing conditions ( + BME). Main bands correspond by molecular mass to neddylated cullins and thioesters with the NEDD8
E2s and E1. (C) NEDD8 overexpression induces strong ectopic NEDDylation (lanes 3 and 4). This type of NEDDylation is resistant to MLN4924 treatment, but strongly reduced by down-regulation
of UBE1 by siRNA. UBE1 is detected in the anti-NEDD8 antibody blot due to a prior Western blot using UBE1 antibody. (D) MG132 treatment induces atypical NEDDylation. U2OS cells were treated
with 30 μM MG132 for 4 h, and with siRNA to UBE1 and MLN4924 as indicated. Widespread UBE1-dependent NEDDylation is apparent after MG132 treatment. Molecular masses in kDa are shown
to the left-hand side of the Western blots. NT, non-transfected.
Genetic alleles of NEDD8 pathway enzymes do not affect atypical
NEDDylation
As MLN4924 treatment only results in transient inhibition of
NAE, we next verified our results using two genetic approaches
to inactivate the enzyme. First, we overexpressed NEDD8 in a
cell line carrying a temperature-sensitive allele of the NEDD8
E1 (CHO ts41) [33]. Consistent with our previous results,
overexpression of NEDD8 induced atypical NEDDylation at
the permissive temperature (32 ◦C), which was unaffected by a
shift to the restrictive temperature (39 ◦C), even though cullin
NEDDylation was strongly decreased (Figure 4A).
Next, we turned to S. cerevisiae, a model system in which
the NEDD8 pathway is not essential. Endogenous expression
of yeast HA–NEDD8 (scNEDD8) revealed that under these
conditions the major substrates for NEDDylation are the cullins
(Figure 4B), whereas overexpression of scNEDD8, but not
of scNEDD8GG, induced atypical NEDDylation similar to
mammalian cells (Figure 4C).
Importantly, deletion of the scNEDD8 E1 uba3 or the single
E2 ubc12 had no effect on atypical NEDDylation, whereas cullin
NEDDylation was absent (Figure 4D). These yeast strains do
not carry functional NEDD8 enzymes, proving unequivocally
that atypical NEDDylation is independent of the classical
NEDD8 E1 and E2. Instead, atypical NEDDylation in yeast was
abolished by a temperature-sensitive allele of the ubiquitin E1
enzyme Uba1 (uba1-204) [34], strongly suggesting that in yeast
atypical NEDDylation is also mediated by ubiquitin enzymes
(Figure 4E).
NEDD8 is present on the active-site cysteine residue of UBE1 from
cells
To unequivocally prove that NEDD8 is activated by UBE in vivo
it is necessary to detect NEDD8 on its active-site cysteine residue.
We thus co-expressed an untagged version of NEDD8 with HA–
UBE1 or HA–UBE1 where the catalytic cysteine residue has been
mutated to serine (HA–UBE1C632S; OXY). This mutant UBE1
can accept the UBL, but forms a non-reducible oxyester with the
modifier. After denaturing immunoprecipitation of HA–UBE1
WT or OXY from cells, we detected a NEDD8 reactive band
co-migrating with HA–UBE1 under non-reducing conditions
(Figure 5A). Under reducing conditions, this NEDD8–UBE1
thioester was strongly diminished, coinciding with the appearance
of free NEDD8 (Figure 5A). For the UBE1 OXY mutant, however,
the reduction did not occur, demonstrating that NEDD8 resides
on the active site of the E1 enzyme. Furthermore, although free
NEDD8 clearly falls off the E1 enzyme under reducing conditions,
additional high molecular mass species of NEDD8 can also be
seen (Figure 5A). We currently have no explanation for this, but
it is tempting to speculate that they are formed prior to activation
by UBE1 and represent forms of NEDD8 much more efficiently
activated by UBE1.
Finally, to test if endogenous NEDD8 is also in principle
available for activation by the ubiquitin-activating enzyme, we
immunoprecipitated HA–UBE1 from cells that had not been co-
transfected with NEDD8. A reducible interaction of endogenous
NEDD8 with HA–UBE1 was indeed detectable (Figure 5B),
demonstrating that NEDD8 is in principle available to UBE1 and
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that under endogenous conditions low UBE1 levels are limiting to
the reaction. Taken together, these experiments demonstrate that,
given the right conditions, NEDD8 can be directly activated by
UBE1 in cells.
Figure 4 Genetic alleles of the NEDD8 pathway do not affect atypical
NEDDylation
(A) Mature NEDD8 and NEDD8GG were overexpressed in CHO TS41 cells harbouring a
temperature-sensitive allele of NAE, and incubated at the permissive (32◦C) and restrictive
(39◦C) temperature, as indicated. A shift to the restrictive temperature does not affect
atypical NEDDylation, suggesting that NEDD8 conjugates are independent of NAE. Importantly,
cullin NEDDylation is strongly reduced at the restrictive temperature. Expression of NEDD8GG
does not induce atypical NEDDylation, indicating that smears observed upon mature NEDD8
expression correspond to conjugates to proteins. (B) Atypical NEDDylation by UBE1 is conserved
in S. cerevisiae. A Western blot using an anti-HA antibody of cells expressing endogenous levels
of untagged or HA-tagged scNEDD8 is shown. The bands detected correspond (by molecular
mass) to NEDDylated cullin proteins. The asterisk denotes the antibody cross-reacting band.
(C) HA–scNEDD8 forms ectopic conjugates upon overexpression (GAL promoter), whereas
the GG version does not. (D) Deletions of the scNEDD8 E2 Ubc12 and E1 Uba3 affect
cullin NEDDylation but not atypical NEDDylation, showing that atypical NEDDylation is strictly
independent of the NEDD8 enzymes. (E) Overexpression of scNEDD8 in a temperature-sensitive
UBA1 mutant (uba1–204) at the restrictive temperature diminishes atypical NEDDylation,
indicating that the ubiquitin E1 enzyme is mediating the formation of atypical NEDD8 conjugates.
Molecular masses are shown in kDa to the left-hand side of the Western blots.
Figure 5 NEDD8 is present on the UBE1 catalytic cysteine in vivo, and
NEDD8 overexpression attenuates proteasomal degradation of a reporter
substrate
(A) Untagged mature NEDD8 was co-expressed with WT HA–UBE1 as well as
with HA–UBE1(C632S; OXY), which forms a non-reducible oxyester with the UBL.
Immunoprecipitation reveals reducible thioester (WT) and non-reducible oxyester (OXY) adducts
with NEDD8. In reducing conditions, free NEDD8 can be seen to fall off the WT HA–UBE1, but not
the oxyester mutant, demonstrating that NEDD8 resides on the catalytic cysteine residue of this
enzyme. Higher molecular mass forms of NEDD8 are also apparent after reduction from UBE1
WT, possibly corresponding to forms of NEDD8 more efficiently activated by UBE1. (B) The
same experiment as described in (A) was performed for WT HA–UBE1, but without simultaneous
NEDD8 overexpression, to investigate if endogenous NEDD8 would be available for activation
upon UBE overexpression. A reducible thioester adduct with endogenous NEDD8 is apparent
after immunopreciptiation (IP), demonstrating that endogenous NEDD8 can be activated when
UBE1 is available. (C) scNEDD8 overexpression attenuates degradation of a Trp1 reporter
substrate. Serial dilution of Trp1 reporter yeast carrying galactose-inducible HA–scNEDD8 or
HA–scNEDD8GG. Induction of HA–scNEDD8 restores growth on − TRP plates, indicating
stabilization of the Trp1 reporter. Deletion of the yeast N-end rule E3 ligase Ubr1 stabilizes
Trp1 and results in loss of tryptophan auxotrophy. (D) Bortezomib treatment induces atypical
NEDDylation. U2OS cells were treated with 3 μM bortezomib or DMSO (vehicle) for 4 h, and
with siRNA to UBE1 and MLN4924 as indicated. Widespread UBE1-dependent NEDDylation is
apparent after bortezomib treatment. Molecular masses in kDa are shown to the left-hand side
of the Western blots. CTRL, control.
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Atypical NEDDylation interferes with ubiquitin-dependent protein
degradation in yeast
On the basis of the extensive atypical NEDDylation pattern
seen on Western blots, it is probable that activation by UBE1
allows NEDD8 to proceed through the ubiquitin pathway on to
many substrates. We thus asked next if this would functionally
interfere with the system. To test this possibility, we used a
yeast reporter strain for proteasomal activity, which cannot grow
on tryptophan-deficient medium due to constitutive proteasomal
degradation of the Trp1 protein by the N-end rule E3 ubiquitin
ligase Ubr1 [35]. If proteasomal degradation is impaired, for
example by deletion of Ubr1, Trp1 is stabilized and growth
restored (Figure 5C). Similarly, growth of this strain was
partially restored upon scNEDD8 overexpression, but not upon
overexpression of scNEDD8GG (Figure 5C), indicating that
atypical NEDDylation indeed interferes with the ubiquitin–
proteasome system, possibly by linking NEDD8 to otherwise
ubiquitylated substrates.
Bortezomib treatment induces atypical NEDDylation
Interference with proteasomal degradation by direct inhibition
of the proteasome is also the mechanism of action of the
anti-cancer drug bortezomib. This drug may thus induce
atypical NEDDylation, similar to what we observed with
MG132. To test this possibility, we exposed cells to 3 μM
bortezomib and followed the NEDDylation pattern by Western
blot analysis. Significant Ube1-dependent NEDDylation was
indeed detectable, concomitant with a drop in free ubiquitin
levels (Figure 5D). We furthermore observed similar results
at a low concentration of bortezomib over a longer period
of treatment (100 nM; see Supplementary Figure S5 at
http://www.BiochemJ.org/bj/441/bj4410927add.htm). Although
experiments with cultured cells are not directly comparable with
drug administration in vivo, the treatment with lower levels of
bortezomib should more accurately reflect the situation in patients.
Our results thus indicate that atypical NEDDylation may also
occur in patients treated with bortezomib. Whether this process
contributes to the efficacy of the drug, however, remains to be
determined.
DISCUSSION
Atypical NEDDylation appears to result in the modification of
a large set of proteins. It is unclear whether substrate specificity
exists or if NEDD8 indiscriminately modifies many, if not all,
ubiquitin substrates. Given that all of the ubiquitin E2 enzymes
we tested were charged with NEDD8 in vitro, it is likely that most
ubiquitin substrates would be modified.
Consequences for the NEDD8 proteome
Previous years have seen a rapid expansion of the reported
NEDDylated proteome. The best-characterized non-cullin
NEDD8 substrate is p53 [16,37], but other proteins have also
been described to be NEDDylated, including BCA3, EGFR and
caspase 7 [19,20,23]. Many of these substrates have also
been shown to be ubiquitylated, and in most cases examined
ubiquitylation and NEDDylation require the same E3 enzyme.
The effect of NEDD8 on these substrates varies. For p53, it seems
to alter its transcriptional profile, whereas for others there is
no obvious effect. In the case of EGFR, for example, NEDD8
and ubiquitin seem to be equally good at inducing receptor
internalization [20]. What all of these substrates have in common
is that their initial characterization and identification was mainly
based on overexpression of a tagged form of NEDD8. Although
still requiring experimental verification, on the basis of our results
it is possible that in those cases NEDDylation was independent
of the NEDD8 pathway, and instead was mediated by ubiquitin
enzymes. This issue equally pertains to the interpretation of large-
scale MS data that was aimed at identifying the NEDDylated
proteome after overexpression of tagged NEDD8 [24]. Additional
work is now required to verify if these reported NEDDylated
proteins are indeed substrates of NEDD8 under endogenous
conditions or whether they only become substrates when the levels
of NEDD8 or ubiquitin are changed.
Alterations of the pool of free NEDD8 and ubiquitin
The results from the present study demonstrate that an altered
NEDD8 to ubiquitin ratio results in atypical NEDDylation.
Particularly, ubiquitin depletion appears to more readily trigger
atypical NEDDylation than increased NEDD8 levels. The
observation that increased expression of UBE1 is sufficient
to activate endogenous NEDD8 may be able to explain this
difference, as it suggests that the availability of UBE1 is limiting
for the reaction in cells. Possibly, the drop in ubiquitin levels
upon MG132 treatment frees up UBE1, making it available for
activation of NEDD8 in the absence of competing ubiquitin. This
raises the possibility that atypical NEDDylation is important
as a response to ubiquitin depletion. For example, in many
neurodegenerative diseases, cells accumulate ubiquitin conjugates
[38] and it is conceivable that under these conditions free
ubiquitin is depleted enough for atypical NEDDylation to occur.
NEDD8 has indeed been found in protein aggregates from many
neurological diseases, including Parkinson’s and Alzheimer’s
[39]. It remains to be seen, however, if any of these conditions
will lead to atypical NEDDylation in vivo and, if so, what the
physiological consequences would be.
Possible functions of UBE1-dependent NEDDylation
Atypical NEDDylation appears to slow proteasome-mediated
degradation of substrates. Given the probable lack of substrate
specificity, this would result in a global attenuation of protein
degradation, which could be its primary function. The mechanism
underlying this effect may be that NEDD8 is a poor substitute
for ubiquitin in the ubiquitin proteasome system. As UBE1 will
activate NEDD8 and ubiquitin in parallel, chains formed on
substrates possibly consist of both UBLs, resulting in mixed
chains. NEDD8 itself is a very poor substrate for ubiquitylation
in vitro [8,40], suggesting that the addition of NEDD8 to a
ubiquitin moiety would slow chain extension and effectively
terminate chains akin to what has been suggested for SUMO1 and
SUMO chains [41]. Terminating chains before they reach a critical
length for proteasome recognition could be one way of slowing
degradation. Furthermore, one could imagine that proteasome-
bound deubiquitinating enzymes less efficiently process NEDD8,
which could also slow degradation of a substrate.
It is also possible that under ubiquitin-depletion stress, atypical
NEDDylation serves as a generalized response to preserve a
pool of free ubiquitin by terminating or slowing ubiquitin
chain elongation on substrates. The effect we saw in yeast
on stability of the Trp1 reporter could in this case just be a
secondary consequence of an attempt of the cell to preserve free
ubiquitin. Although highly speculative, these options are attractive
possibilities, but require further investigations for verification.
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Implications for therapeutic interventions
Irrespective of its physiological role, atypical NEDDylation will
probably occur in therapeutic settings where the intracellular
ubiquitin to NEDD8 ratio is affected. On the basis of the results
from the present study, it is conceivable that not only bortezomib,
but also other proteasome inhibitors currently in development,
such as MLN9708, carfilzomib or CEP-18770, will lead to
induction of atypical NEDDylation. The consequences of this are
currently not possible to predict, but it is tempting to speculate
that bortezomib-induced NEDDylation of ubiquitin substrates
has an impact on the therapeutic outcome of this and similar
drugs. For example, it may further slow the degradation of p53
and/or other tumour suppressors. Although speculative, atypical
NEDDylation may indeed persist even after the direct inhibition of
the proteasome has worn off, effectively prolonging the inhibition
of protein degradation.
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Figure S1 Evaluation of anti-NEDD8 and -ubiquitin antibodies
(A) Silver stain of NEDD8 and ubiquitin amounts used. (B) A panel of anti-NEDD8 and anti-ubiquitin antibodies were tested for specificity on 0.5 μg of purified NEDD8 (N) or ubiquitin (U). All tested
antibodies were specific for their respective target, with the exception of the P4D1 anti-ubiquitin antibody from Santa Cruz, which cross-reacts heavily with NEDD8. (C) The same panel of antibodies
was tested on U20S whole cell lysates. Cells were either treated with 3 μM MLN4924 or DMSO (vehicle) to control for antibody specificity. The non-commercial MIL-10 anti-NEDD8 antibody
(provided by Millennium Pharmaceuticals) was found to be the most potent, and also was the only option that detected free NEDD8 using these settings. Molecular masses in kDa are shown to the
left-hand side of the Western blots.
1 To whom correspondence should be addressed (email t.kurz@dundee.ac.uk).
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Figure S2 Measurement of endogenous free ubiquitin and NEDD8
concentrations in MCF7 cells
Measurements were performed under non-reducing conditions. Roughly equimolar
concentrations of both UBLs were detected. Error bars indicate +− S.D. Figure S3 A typical NEDDylation is not induced by overexpression of
NEDD8GG, and reduced by treatment with PYR-41
(A) Mature NEDD8 and NEDD8GG were overexpressed in U2OS cells. Widespread
NEDDylation is apparent after mature NEDD8 overexpression, but not after NEDD8GG
overexpression. (B) Treatment with the UBE1 inhibitor PYR-41, but not MLN4924 or DMSO,
reduces atypical NEDDylation after NEDD8 overexpression. Molecular masses in kDa are shown
to the left-hand side of the Western blots.
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Figure S4 Assessment of contribution of UBA6 to NEDD8 smears and cell
type dependence
HeLa, HEK-293 and U20S cell lines were tested. Knockdown of UBE1 or UBA6 (UBE1L2) was
performed 48 h prior to transfection with NEDD8, and whole cell lysates were analysed for
NEDD8 by Western blotting.
Figure S5 A low concentration of bortezomib induces atypical NEDDylation
U2OS cells were treated with bortezomib (100 nM, 20 h) or DMSO (vehicle) and siRNA to UBE1
or MLN4924 as indicated. NEDDylation induced by bortezomib treatment is independent of NAE,
whereas it is diminished upon ubiquitin E1 siRNA. Molecular masses in kDa are shown to the
left-hand side of the Western blot.
Received 16 September 2011; accepted 17 October 2011
Published as BJ Immediate Publication 17 October 2011, doi:10.1042/BJ20111671
Table S1 Human E2 enzymes tested for capacity to accept NEDD8 from
UBE1 in vitro
+ or − indicates whether the E2 could or could not accept NEDD8 from UBE1 respectively.
E2 NEDD8 chargable
Ube2A +
Ube2B +
Ube2D1 +
Ube2L3 +
Ube2I −
Ube2L6 +
Ube2N +
Ube2D4 +
Ube2C +
Ube2G1 +
Ube2K +
Ube2E3 +
Ube2D2 +
Ube2Q2 +
Ube2E1 +
Ube2H +
Ube2s +
Ube2N/V1 +
Ube2G +
Ube2Q +
Ube2E2 +
Ube2T +
Ube2M −
Ube2F −
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